Generex Biotechnology Corporation (NASDAQ: GNBT) announced today that it has received an aggregate of $11 million as a result of the exercise by existing Company investors of previously issued warrants. The receipt of these funds has put the Company’s cash-on-hand at more than $31 million, its strongest cash position in more than four years.
